Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

  • There is currently no data for NSCI

Director/PDMR Shareholding

16 Jul 2021 10:35

RNS Number : 4893F
NetScientific PLC
16 July 2021
 

NetScientific plc

("NetScientific" or the "Company")

Director/PDMR Shareholding

London, UK - 16 July 2021 - NetScientific plc (AIM: NSCI), the international life sciences and sustainability technology investment and commercialisation Group, announces that John Clarkson, Executive Chairman, purchased 10,000 ordinary shares of £0.05 each in the Company ("Ordinary Shares") at a price of £1.01 per Ordinary Share on 15 July 2021.

Following this transaction, John Clarkson will hold in aggregate 136,066 Ordinary Shares in the Company, equal to approximately 0.65% of the Company's issued share capital.

For more information, please contact:

NetScientific

Via Walbrook PR

Ilian Iliev, CEO 

WH Ireland (NOMAD, Financial Adviser and Broker)

Chris Fielding / Darshan Patel 

+44 (0)20 7220 1666

Walbrook PR

Nick Rome/ Paul McManus/

Nicholas Johnson

07748 325 236, 07980 541 893

or 07884 664 686

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

a)

 

Name

John Clarkson

2

 

Reason for the notification

a)

 

Position/status

Executive Chairman

b)

 

Initial notification /Amendment

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

 

Name

NetScientific plc

b)

 

LEI

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted 

a)

 

Description of the financial instrument, type of instrument 

Identification code

 

Ordinary Shares of ÂŁ0.05 each

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of Shares

c)

 

Price(s) and volume(s)

 

Price(s)

Volume(s)

ÂŁ1.01

10,000 Ordinary Shares

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

15 July 2021

f)

 

Place of the transaction

UK AIM

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFLSUMEFSEDW
Date   Source Headline
16th Sep 20242:31 pmRNSPDS: Updated Results, VERSATILE-002 Phase 2 Trial
13th Aug 20243:57 pmRNSPDS Biotech: Business Update and Q2 2024 Results
2nd Aug 202412:21 pmRNSReplacement RNS: PDS Biotech Aligns with FDA
2nd Aug 20247:00 amRNSPDS Biotech Aligns with FDA on Phase 3 Trial
30th Jul 20247:00 amRNSQ-Bot Fundraising
10th Jul 202410:48 amRNSResult of AGM
18th Jun 20247:00 amRNSNotice of AGM
14th Jun 20242:10 pmRNSTR-1
14th Jun 20247:00 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSPreliminary Results for the year ended 31 Dec 2023
31st May 20247:01 amRNSNotice of Results and Investor Presentation
31st May 20247:00 amRNSDeepTech Recycling: Fundraising, Business Update
28th May 20247:00 amRNSInvestment in Wanda, related party transactions
15th May 20242:32 pmRNSPDS Biotech: Business Update and Q1 2024 Results
13th May 20247:00 amRNSMartlet Capital: mandate and acquisition
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.